NASDAQ:RLYB Rallybio (RLYB) Stock Price, News & Analysis $0.73 0.00 (-0.05%) As of 03:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Rallybio Stock (NASDAQ:RLYB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rallybio alerts:Sign Up Key Stats Today's Range$0.70▼$0.7750-Day Range$0.63▼$1.0052-Week Range$0.62▼$3.46Volume19,520 shsAverage Volume474,649 shsMarket Capitalization$30.45 millionP/E RatioN/ADividend YieldN/APrice Target$9.75Consensus RatingModerate Buy Company OverviewRallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.Read More… Remove Ads Rallybio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreRLYB MarketRank™: Rallybio scored higher than 50% of companies evaluated by MarketBeat, and ranked 574th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingRallybio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRallybio has only been the subject of 1 research reports in the past 90 days.Read more about Rallybio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rallybio are expected to grow in the coming year, from ($1.34) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rallybio is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rallybio is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRallybio has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Rallybio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.65% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Rallybio has recently increased by 1.93%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRallybio does not currently pay a dividend.Dividend GrowthRallybio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.65% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Rallybio has recently increased by 1.93%, indicating that investor sentiment is decreasing. News and Social Media2.0 / 5News Sentiment0.67 News SentimentRallybio has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Rallybio this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for RLYB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rallybio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.40% of the stock of Rallybio is held by insiders.Percentage Held by Institutions90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rallybio's insider trading history. Receive RLYB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter. Email Address RLYB Stock News HeadlinesRallybio's (RLYB) "Buy" Rating Reiterated at HC WainwrightMarch 18 at 1:55 AM | americanbankingnews.comRallybio reports Q4 EPS (25c), consensus (30c)March 13, 2025 | markets.businessinsider.comNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.March 19, 2025 | Brownstone Research (Ad)Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 13, 2025 | finance.yahoo.comRallybio to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | finance.yahoo.comRallybio to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | businesswire.comRallybio stock plunges to 52-week low of $0.73 amid market challengesFebruary 13, 2025 | msn.comJMP Securities Sticks to Their Buy Rating for Rallybio (RLYB)February 11, 2025 | markets.businessinsider.comSee More Headlines RLYB Stock Analysis - Frequently Asked Questions How have RLYB shares performed this year? Rallybio's stock was trading at $0.96 at the beginning of the year. Since then, RLYB stock has decreased by 24.3% and is now trading at $0.7270. View the best growth stocks for 2025 here. How were Rallybio's earnings last quarter? Rallybio Co. (NASDAQ:RLYB) issued its earnings results on Thursday, March, 13th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02. The business earned $0.04 million during the quarter, compared to analyst estimates of $0.15 million. When did Rallybio IPO? Rallybio (RLYB) raised $80 million in an initial public offering on Thursday, July 29th 2021. The company issued 5,750,000 shares at a price of $13.00-$15.00 per share. Who are Rallybio's major shareholders? Top institutional shareholders of Rallybio include Canaan Partners XI LLC (4.09%), Almitas Capital LLC (3.13%), Allostery Investments LP (1.94%) and Renaissance Technologies LLC (1.06%). Insiders that own company stock include Kush Parmar, Jonathan I Lieber and Jeffrey M Fryer. View institutional ownership trends. How do I buy shares of Rallybio? Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rallybio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rallybio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Plug Power (PLUG). Company Calendar Last Earnings3/13/2025Today3/19/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLYB CIK1739410 Webwww.rallybio.com Phone203-59-3820FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$9.75 High Stock Price Target$15.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,241.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,560,000.00 Net MarginsN/A Pretax Margin-10,794.48% Return on Equity-77.39% Return on Assets-69.33% Debt Debt-to-Equity RatioN/A Current Ratio9.55 Quick Ratio9.55 Sales & Book Value Annual Sales$636,000.00 Price / Sales47.42 Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.26Miscellaneous Outstanding Shares41,488,000Free Float38,418,000Market Cap$30.16 million OptionableNot Optionable Beta-1.45 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:RLYB) was last updated on 3/19/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.